[LAUREN TAYLOR]

THE U-S SUPREME COURT IS SET TO HEAR ITS FIRST ABORTION CASE SINCE ITS CONTROVERSIAL DOBBS DECISION OVERTURNING ROE VERSUS WADE.

THE HIGH COURT ANNOUNCED IT WILL HEAR ORAL ARGUMENTS – IN THE CASE OF ACCESS TO AN ABORTION DRUG – CALLED “MIFEPRISTONE” – ON MARCH 26TH.

MIFEPRISTONE IS ONE OF TWO ABORTION DRUGS THAT’S USED TO END A PREGNANCY…
AND ACCORDING TO THE MAYO CLINIC – “IT WORKS BY STOPPING THE SUPPLY OF HORMONES THAT MAINTAINS THE INTERIOR OF THE UTERUS. WITHOUT THESE HORMONES, THE UTERUS CANNOT SUPPORT THE PREGNANCY AND THE CONTENTS OF THE UTERUS ARE EXPELLED.”

MIFEPRISTONE HAS BEEN USED IN 5-MILLION ABORTION CASES AND THE FDA SAYS ADVERSE EVENTS ASSOCIATED WITH USE OF THE DRUG ARE LOW.

MEDICATION ABORTIONS ACOCUNT FOR HALF OF ABORTIONS IN THE UNITED STATES – ACCORDING TO THE CDC.

SO HOW DID WE GET HERE?

THE FDA APPROVED MIFEPRISTONE FOR USE IN THE YEAR 2000.

IN JUNE 2022 – THE SUPREME COURT OVERTURNED ROE, SAYING THE CONSTITUTION DOES NOT CONFER A RIGHT TO ABORTION

THEN – IN NOVEMBER 2022 – A GROUP OF PHYSICIANS with the alliance for hippocratic medicine – which OPPOSEs ABORTION – BROUGHT A CHALLENGE AGAINST THE FDA’S 2000 APPROVAL OF MIFEPRISTONE.

THE GROUP ARGUED – THE FDA DID NOT CONSIDER THE SAFETY OF MIFEPRISTONE BEFORE APPROVING THE DRUG FOR USE. THE DOCTORS ALSO ARGUED TO ROLL BACK STEPS THE FDA HAS TAKEN SINCE 2016 – THAT MADE MIFEPRISTONE EASIER TO OBTAIN AND, THEY SAY, MORE UNSAFE FOR PATIENT USE. THOSE STEPS INCLUDED – ALLOWING THE PILL TO BE TAKEN LATER IN PREGNANCY AT 10 WEEKS – AS OPPOSED TO 7 WEEKS… CREATING A GENERIC VERSION OF THE DRUG… AND ALLOWING DOCTORS TO PRESCRIBE IT AND DISTRIBUTE IT BY MAIL.

IN APRIL 2023 – A U.S. DISTRICT COURT JUDGE IN TEXAS PUT A HOLD ON THE FDA’S 2000 APPROVAL OF MIFEPRISTONE.

THE BIDEN ADMINISTRATION THEN APPEALED TO THE 5TH CIRCUIT COURT OF APPEALS.

[XAVIER BECERRA / HHS SECRETARY]
“FIRST AND FOREMOST, WHEN YOU TURN UPSIDE DOWN THE ENTIRE FDA APPROVAL PROCESS, YOU’RE NOT TALKING ABOUT JUST MIFEPRISTONE, YOU’RE TALKING ABOUT EVERY KIND OF DRUG. YOU’RE TALKING ABOUT OUR VACCINES, YOU’RE TALKING ABOUT INSULIN, YOU’RE TALKING ABOUT THE NEW ALZHEIMER’S DRUGS THAT MAY COME ON. IF A JUDGE DECIDES TO SUBSTITUTE HIS PREFERENCES, HIS PERSONAL OPINION, FOR THAT OF SCIENTISTS AND MEDICAL PROFESSIONALS, WHAT DRUG ISN’T SUBJECT TO SOME KIND OF LEGAL CHALLENGE, SO WE HAVE TO GO TO COURT. AND FOR WOMEN’S SAKE, WE HAVE TO PREVAIL IN THIS.”

[LAUREN TAYLOR]

THEN – THE 5TH CIRCUIT COURT OF APPEALS ruled THE FDA’S ORIGINAL APPROVAL OF MIFEPRISTONE IN 2000 WOULD REMAIN IN EFFECT – HOWEVER – THE 3-JUDGE-PANEL NULLIFIED THE CHANGES PUT IN PLACE BY THE FDA – THAT MADE MIFEPRISTONE EASIER TO ACCESS IN 2016.

THE ADMINISTRATION THEN ARGUED – IF THOSE RESTRICTIONS ARE ALLOWED TO TAKE PLACE – IT WOULD CAUSE WIDESPREAD CHAOS.

SO — THE SUPREME COURT THEN INTERVENED – AND BLOCKED THAT RULING – ALLOWING MIFEPRISTONE TO STAY ON THE MARKET WITH NO CHANGES TO HOW IT’S PRESCRIBED – WHILE THE CASE PLAYS OUT IN THE LOWER COURTS.

MIFEPRISTONE’S MANUFACTURER – danco LABORATORIES AND THE DEPARTMENT OF JUSTICE – ASKED THE SUPREME COURT TO REVIEW THE 5TH CIRCUIT COURT’S RULING – WHICH THE HIGH COURT AGREED TO DO IN DECEMBER.

ORAL ARGUMENTS ARE SET FOR MARCH – AND A DECISION IS LIKELY TO COME DOWN IN JUNE.